Up to 90% of people with dementia develop at least one behavioral or psychological symptom, such as psychosis, anxiety or agitation/aggression, which often overlap and worsen both patient quality of life and caregiver burden. Based on preclinical evidence, dual 5-HT2A/7 receptor antagonism may represent a rational strategy to modulate psychosis, agitation and mood-related symptoms.